Strategy purchased $82 million in Bitcoin and repurchased $188.3 million of STRC
Decrypt
16m ago
Ai Focus
According to documents submitted to the U.S. Securities and Exchange Commission, Strategy purchased 1,036 bitcoins between November 2nd and November 8th, costing $81.9 million; the company also repurchased $188.3 million worth of STRC preferred stocks. Both transactions were mainly financed by selling 2,051,348 shares of MSTR stock. As of November 8th, Strategy held 850,364 bitcoins, with a total purchase cost of $64.16 billion, averaging approximately $75,456 per bitcoin.
Helpful
No.Help

Abstract

  • According to documents submitted to the U.S. Securities and Exchange Commission, Strategy purchased 1,036 bitcoins between November 2nd and November 8th, spending $81.9 million, which represents the second consecutive week of such purchases by the company.
  • The company also repurchased $188.3 million worth of STRC preferred stock, and the funds for these two operations came from the sale of 2,051,348 shares of MSTR stock.
  • Strategy currently holds 850,364 Bitcoin coins, with a total purchase cost of 64.16 billion US dollars, averaging approximately 75,456 US dollars per coin.

Strategy reported that the company purchased 1,036 bitcoins last week, spending $81.9 million, which is the second consecutive week they have made such purchases.

According to documents submitted to the U.S. Securities and Exchange Commission, Strategy purchased bitcoins at an average price of $79,012 each from November 2 to November 8. The company currently holds 850,364 bitcoins, with a total purchase cost of $64.16 billion, averaging about $75,456 per coin.

Strategy posted on a social media platform stating: " Strategy has purchased 1,036 BTC and repurchased $188 million worth of STRC. As of November 8, 2026, we hold 850,364 BTC as well as $4.9 billion in US dollar assets."

The scale of this purchase is higher than that of the previous week. In the week prior, Strategy resumed purchases after a one-week pause and acquired 811 bitcoins for $65.5 million.

Strategy also repurchased 1,887,464 shares of STRC. STRC is the company's floating-rate preferred stock, with a repurchase amount of $188.3 million, which is lower than the $208.2 million of the previous week. The company obtained net income of $283.8 million by selling 2,051,348 shares of MSTR stock, which was used to pay for the Bitcoin purchases and share repurchases. The remaining $13.6 million was credited to its US dollar cash account.

This is different from last week. At that time, Strategy repurchased STRC with US dollar cash, reducing the account balance to $132.7 million. With a new round of financing in place, as of November 8th, the US dollar cash balance had risen to $146.2 million.

Strategy A separate reserve of US dollars is established to cover the dividends on its preferred stock and debt interest. After paying $21.1 million in preferred stock dividends that week, the balance of this reserve was $4.77 billion. There is still approximately $560.3 million available under its preferred stock repurchase plan, and $1 billion is available under the MSTR stock repurchase plan.

As of the release of this update, there are only two days left until index provider MSCI publishes a list of companies affected by its new regulations targeting "companies dominated by a single asset." These new regulations may result in Strategy being removed from its stock index.

The preferred stocks of Strategy are also undergoing adjustments to their payment arrangements. Last month, shareholders approved a change to daily dividend payments for its four preferred stocks, with STRC having already commenced this practice on November 1st.

Tip
$0
Like
0
Save
0
Views 15
CoinMeta reminds readers to view blockchain rationally, stay aware of risks, and beware of virtual token issuance and speculation. All content on this site represents market information or related viewpoints only and does not constitute any form of investment advice. If you find sensitive content, please click“Report”,and we will handle it promptly。
Submit
Comment 0
Hot
Latest
No comments yet. Be the first!
Related
QVC Group Announces the Submission Date for the 10-Q Report of the Third Quarter of Fiscal Year 2026 and the Date of the Web Audio Conference
QVC Group indicates that the company will submit its 10-Q report for the third quarter of fiscal year 2026 to the U.S. Securities and Exchange Commission on Monday, November 16, 2026, and will also release a performance review audio on its investor relations website, which will be presented by the interim CEO who also serves as Chairman Mike George and CFO Bill Wafford.
PR Newswire
·2026-11-09 21:52:32
6
Cellebrite will release its financial report for the third quarter of 2026 on November 12, 2026
Cellebrite indicates that the company will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 12, 2026, and will also hold a conference call and webcast later on the same day to review the quarterly results and discuss the outlook for 2026.
PR Newswire
·2026-11-09 21:52:26
8
Cellebrite will release its financial report for the third quarter of 2026 on November 12, 2026
Cellebrite DI Ltd. It is indicated that the financial report for the third quarter of 2026 will be released on November 12, 2026, before the opening of the U.S. stock market. A conference call and webcast will also be held later on the same day to discuss the performance and annual outlook. The company stated that, aside from the dial-in numbers for analysts and investors, the details of the event remain unchanged.
PR Newswire
·2026-11-09 21:52:25
9
IceCure Approves New Patent in China, Expanding Its Global Intellectual Property Portfolio
According to IceCure Medical, the National Intellectual Property Administration of China has granted the company a new patent covering a connector within its low-temperature technology platform. The company stated that this patent will further expand its global intellectual property portfolio and strengthen its protection of proprietary low-temperature technologies in key international markets. The company also mentioned that in September 2026, it received approval from the National Medical Products Administration of China to sell ProSense ® and related cryoprobe products in China.
PR Newswire
·2026-11-09 21:43:19
13
View More